

This document is approved by The Executive Directorate of Pharmacovigilance, at SFDA

FA-11734595

PATIENT ALERT CARD

Have This Card With You At All Times



Kymriah® (tisagenlecleucel) SFDA approved RMP Educational Materials V 1.3 Jan 2021

This document has been approved by Saudi Food and Drug Authority (SFDA).

PATIENT ALERT CARD Have This Card With You At All Times

My name is: _____

I have been treated with KYMRIA[®], an immunocellular therapy containing genetically modified autologous T cells.

Batch ID: _____

Date of treatment: _____

KYMRIA[®] treating physician's name and contact details: _____

Before providing any treatment, please call my treating physician at the number above. When reporting possible side effects, please include the individual Batch ID printed above. I should not donate blood, organs, tissues, or cells.



INFORMATION FOR THE HEALTHCARE PROVIDER

This patient has received KYMRIA[®] (tisagenlecleucel), an autologous CAR-T cell therapy. This patient should not donate blood, organs, tissues, or cells.

Before providing any treatment, call the treating physician at the number on the front of the card.

If any side effects appear, inform your doctor, pharmacist or nurse, even if the side effect is not mentioned in the accompanying Patient Information Leaflet

When reporting possible side effects, please include the individual Batch ID printed on the front of this card.

 **NOVARTIS** | Reimagining Medicine

Novartis Saudi Limited **نوفارتس السعودية لميتد**

Building no. 7892, Secondary no. 2274

B-11 Layen Valley

West Umm Al Hamam District

Postal Code 12329, Riyadh, SAUDI ARABIA

<Contacts are inserted on the next page>

**You can report any problem or adverse events or
request additional copies of the materials through:**

Saudi Food and Drug Authority National Pharmacovigilance Center

Unified Contact Center: 19999

Email: npc.drug@sFDA.gov.sa

Website: <https://ade.sFDA.gov.sa>



Patient Safety Department Novartis Saudi Limited - Saudi Arabia.

Toll Free Number: 8001240078

Phone: +966112658100

Fax: +966112658107

Email: adverse.events@novartis.com

Website: <http://report.novartis.com/>



Kymriah® (tisagenlecleucel) SFDA approved RMP Educational Materials V 1.3 Jan 2021